GGrantIndex
← Leaderboards

Elisabeth Ann Tallant

Wake Forest University

$3,392,401
Attributed
$3,982,428
Total exposure
5
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $344.7K · FY200520
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$3,982,428 · 5

By mechanism

P01$2,658,624 · 3
R25$1,180,054 · 1
R03$143,750 · 1

Top collaborators

Most similar at Wake Forest University

Same institution · by research overlap

Others in their field

Top investigators on “Blood Vessels

Research focus

Blood VesselsHypertensionFundingAgingNeonatalMemberFetalPathologyAngiotensinsCardiovascular SystemExposure ToCardiovascular DiseasesInvestigationBiomedical ResearchJournalsForestAreaDoctor Of PhilosophyFosteringBasic ScienceExtramural ActivitiesBehavioral SciencesDesignFaculty

Grant awards (28)

Excellence in Cardiovascular Sciences Summer Research$108,734
R25 · FY2020 · HL · contact PI
Excellence in Cardiovascular Sciences Summer Research$105,494
R25 · FY2019 · HL · contact PI
Excellence in Cardiovascular Sciences Summer Research$105,494
R25 · FY2018 · HL · contact PI
Excellence in Cardiovascular Sciences Summer Research$92,653
R25 · FY2017 · HL · contact PI
Excellence in Cardiovascular Sciences Summer Research$92,653
R25 · FY2016 · HL · contact PI
Excellence in Cardiovascular Sciences Summer Research$92,653
R25 · FY2015 · HL · contact PI
Excellence in Cardiovascular Sciences Summer Research$92,653
R25 · FY2014 · HL · contact PI
Angiotensin-(1-7) Inhibition of Hypertrophy & Fibrosis$236,253
P01 · FY2013 · HL · contact PI
Excellence in Cardiovascular Sciences Summer Research$75,000
R25 · FY2013 · HL · contact PI
Angiotensin-(1-7) Inhibition of Hypertrophy & Fibrosis$261,761
P01 · FY2012 · HL · contact PI
Excellence in Cardiovascular Sciences Summer Research$82,944
R25 · FY2012 · HL
Angiotensin-(1-7) Inhibition of Hypertrophy & Fibrosis$258,266
P01 · FY2011 · HL · contact PI
Excellence in Cardiovascular Sciences Summer Research$82,944
R25 · FY2011 · HL
Angiotensin-(1-7) Inhibition of Hypertrophy & Fibrosis$245,468
P01 · FY2010 · HL · contact PI
Excellence in Cardiovascular Sciences Summer Research$82,944
R25 · FY2010 · HL
Angiotensin-(1-7) Inhibition of Hypertrophy/ Fibrosis$245,468
P01 · FY2009 · HL · contact PI
Excellence in Cardiovascular Sciences Summer Research$82,944
R25 · FY2009 · HL
Cardiac Growth and Angiotensin-(1-7)$239,884
P01 · FY2008 · HL · contact PI
Excellence in Cardiovascular Sciences Summer Research$82,944
R25 · FY2008 · HL
Cardiac Growth and Angiotensin-(1-7)$241,276
P01 · FY2007 · HL · contact PI
Cardiac Growth and Angiolensin- (1-7)$166,984
P01 · FY2006 · HL · contact PI
Cardiac Growth and Angiolensin- (1-7)$162,415
P01 · FY2005 · HL
Cardiac Growth and Angiolensin- (1-7)$157,759
P01 · FY2004 · HL
Prevention of Lung Cancer Growth by Angiotensin-(1-7)$71,750
R03 · FY2004 · CA
Prevention of Lung Cancer Growth by Angiotensin-(1-7)$72,000
R03 · FY2003 · CA
ANGIOTENSIN-(1-7) AND REGULATION OF VASCULAR GROWTH$131,864
P01 · FY2002 · HL
ANGIOTENSIN-(1-7) AND REGULATION OF VASCULAR GROWTH$131,864
P01 · FY2001 · HL
ANGIOTENSIN-(1-7) AND REGULATION OF VASCULAR GROWTH$179,362
P01 · FY2000 · HL